Table 1.

Comparison of antitumor activity of evofosfamide and ifosfamide alone, or in combination with docetaxel in the metastatic H460 intrapleural model.

	MST (Day)	T/C%	ILS%
Vehicle	22
Evofosfamide 50 mg/kg	43*	200*	100
Ifosfamide 120 mg/kg	34	158	58
Docetaxel 5 mg/kg	32	149	49
Evo 50 mg/kg + Doc 5 mg/kg	47*,#	216*,#	116
Evo 25 mg/kg + Doc 5 mg/kg	40*	184*	84
Ifo 120 mg/kg + Doc 5 mg/kg	39	181	81
Ifo 60 mg/kg + Doc 5 mg/kg	30	140	40

MST: Median Survival Time

T/C%: MST of treated group/MST of Vehicle Group × 100

ILS: Increase in life span, ILS=T/C%-1

Evo: evofosfamide

Ifo: ifosfamide

Doc: docetaxel

*, p < 0.05 vs. vehicle

^#, p < 0.05 vs. same dose of monotherapy